Rock Creek Pharmaceuticals, Inc.

RCPIQ

US7720812046

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

2020	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
2020	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Rock Creek Pharmaceuticals, Inc. announced that it has received $20 million in funding from Hudson Bay Capital Management LP. and other investors.

October 14, 2015

On October 15, 2015, Rock Creek Pharmaceuticals, Inc. closed the transaction. The company paid $1,500,000 to Maxim Group LLC as sales commission.

Latest news about Rock Creek Pharmaceuticals, Inc.

Rock Creek Pharmaceuticals, Inc. Went Out of Business	08/12/20	CI
Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	06/02/20	CI
Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	21/12/18	CI
Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	11/01/18	CI
Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	27/09/16	CI
Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	29/08/16	CI
Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	10/08/16	CI
Rock Creek Pharmaceuticals, Inc. Announces Board Changes	08/07/16	CI
Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	08/06/16	CI
Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	29/03/16	CI
Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	22/03/16	CI
Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	21/03/16	CI
Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	19/11/15	CI
Rock Creek Pharmaceuticals, Inc.(OTCPK:RCPI) dropped from MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	06/11/15	CI
Rock Creek Pharmaceuticals, Inc.(OTCPK:RCPI) dropped from S&P TMI Index	06/11/15	CI
Rock Creek Pharmaceuticals, Inc.(OTCPK:RCPI) dropped from CRSP US Total Market Index	05/11/15	CI
Rock Creek Pharmaceuticals, Inc.(NasdaqCM:RCPI) dropped from NASDAQ Composite Index	04/11/15	CI
Rock Creek Pharmaceuticals, Inc. announced that it has received $20 million in funding from Hudson Bay Capital Management LP. and other investors.	14/10/15	CI
Rock Creek Pharmaceuticals, Inc. announced that it expects to receive $20 million in funding from Hudson Bay Capital Management LP, and other investors.	13/10/15	CI
Certain Common Stock of Rock Creek Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-SEP-2015.	13/09/15	CI
Rock Creek Pharmaceuticals, Inc. Announces Executive Changes	20/08/15	CI
Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2015; Announces Targeting of Dermatological Disease, Updated Clinical and Regulatory Strategy	10/08/15	CI
Rock Creek Pharmaceuticals, Inc. Announces an Update on its Clinical and Regulatory Drug Development Activities	11/06/15	CI
Rock Creek Pharmaceuticals, Inc. Announces Executive Changes	10/06/15	CI
Rock Creek Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015	27/05/15	CI

Chart Rock Creek Pharmaceuticals, Inc.

Duration

Period

More charts

Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCK CREEK PHARMACEUTICALS, INC.	-.--%	17.04K
NOVO NORDISK A/S	+31.37%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	211B
ROCHE HOLDING AG	-6.95%	203B
AMGEN INC.	+10.77%	171B
PFIZER, INC.	+0.10%	163B

Other Pharmaceuticals